Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
Figure 6
(a) Overall survival (OS) of patients with a mono-15 ≥ 450 cells/L versus patients with a mono-15 < 450 cells/L. The median OS was not reached in the group of patients with a mono-15 ≥ 450 cells/L and 12.6 months with the group of patients with a mono-15 < 450 cells/L. The OS rates at 3 years were 70% and 42%, respectively (01). (b) Progression-free survival (PFS) of patients with a mono-15 ≥ 450 cells/L versus patients with a mono-15 < 450 cells/L. The median PFS was not reached in the group of patients with a mono-15 ≥ 450 cells/L and 4.5 months with the group of patients with a mono-15 < 450 cells/L. The PFS rates at 3 years were 71% and 33%, respectively (02).
